Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis.
<h4>Objective</h4>To search, review, and analyze the efficacy and safety of various anticoagulants from randomized clinical trials (RCTs) of anticoagulants for THA and TKA.<h4>Design</h4>PRISMA-compliant Bayesian Network Meta-analysis.<h4>Data sources and study selectio...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0250096&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839655803228782592 |
|---|---|
| author | Tailai He Fei Han Jiahao Wang Yihe Hu Jianxi Zhu |
| author_facet | Tailai He Fei Han Jiahao Wang Yihe Hu Jianxi Zhu |
| author_sort | Tailai He |
| collection | DOAJ |
| description | <h4>Objective</h4>To search, review, and analyze the efficacy and safety of various anticoagulants from randomized clinical trials (RCTs) of anticoagulants for THA and TKA.<h4>Design</h4>PRISMA-compliant Bayesian Network Meta-analysis.<h4>Data sources and study selection</h4>The databases of The Medline, Embase, ClinicalTrial, and Cochrane Library databases were searched until March 2017 for RCTs of patients undergoing a THA or TKA.<h4>Main outcomes and measures</h4>The primary efficacy measurement was the venous thromboembolism Odds ratio (OR). The safety measurement was the odds ratio of major or clinically relevant bleeding. OR with 95% credibility intervals (95%CrIs) were calculated. Findings were interpreted as associations when the 95%CrIs excluded the null value.<h4>Results</h4>Thirty-five RCTs (53787 patients; mean age range, mostly 55-70 years; mean weight range, mostly 55-90 kg; and a higher mean proportion of women than men, around 60%) included the following Anticoagulants categories: fondaparinux, edoxaban, rivaroxaban, apixaban, dabigatran, low-molecular-weight heparin, ximelagatran, aspirin, warfarin. Anticoagulants were ranked for effectiveness as follows: fondaparinux (88.89% ± 10.90%), edoxaban (85.87% ± 13.34%), rivaroxaban (86.08% ± 10.23%), apixaban (68.26% ± 10.82%), dabigatran (41.63% ± 12.26%), low-molecular-weight heparin (41.03% ± 9.60%), ximelagatran (37.81% ± 15.87%), aspirin (35.62% ± 20.60%), warfarin (9.89% ± 9.07%), and placebo (4.56% ± 6.37%). Ranking based on clinically relevant bleeding events was as follows: fondaparinux (14.53% ± 15.25%), ximelagatran (18.93% ± 17.49%), rivaroxaban (23.86% ± 15.14%), dabigatran (28.30% ± 14.18%), edoxaban (38.76% ± 24.25%), low-molecular-weight heparin (53.28% ± 8.40%), apixaban (71.81% ± 10.92%), placebo (76.26% ± 14.61%), aspirin (86.32% ± 25.74%), and warfarin (87.95% ± 11.27%). No statistically significant heterogeneity was observed between trials.<h4>Conclusions and relevance</h4>According to our results, all anticoagulant drugs showed some effectiveness for VTE prophylaxis. Our ranking indicated that fondaparinux and rivaroxaban were safer and more effective than other anticoagulant drugs for patients undergoing THA or TKA. |
| format | Article |
| id | doaj-art-b109ba8aa6d24c1f8b75c0ab40a067f5 |
| institution | Matheson Library |
| issn | 1932-6203 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-b109ba8aa6d24c1f8b75c0ab40a067f52025-06-25T05:31:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01166e025009610.1371/journal.pone.0250096Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis.Tailai HeFei HanJiahao WangYihe HuJianxi Zhu<h4>Objective</h4>To search, review, and analyze the efficacy and safety of various anticoagulants from randomized clinical trials (RCTs) of anticoagulants for THA and TKA.<h4>Design</h4>PRISMA-compliant Bayesian Network Meta-analysis.<h4>Data sources and study selection</h4>The databases of The Medline, Embase, ClinicalTrial, and Cochrane Library databases were searched until March 2017 for RCTs of patients undergoing a THA or TKA.<h4>Main outcomes and measures</h4>The primary efficacy measurement was the venous thromboembolism Odds ratio (OR). The safety measurement was the odds ratio of major or clinically relevant bleeding. OR with 95% credibility intervals (95%CrIs) were calculated. Findings were interpreted as associations when the 95%CrIs excluded the null value.<h4>Results</h4>Thirty-five RCTs (53787 patients; mean age range, mostly 55-70 years; mean weight range, mostly 55-90 kg; and a higher mean proportion of women than men, around 60%) included the following Anticoagulants categories: fondaparinux, edoxaban, rivaroxaban, apixaban, dabigatran, low-molecular-weight heparin, ximelagatran, aspirin, warfarin. Anticoagulants were ranked for effectiveness as follows: fondaparinux (88.89% ± 10.90%), edoxaban (85.87% ± 13.34%), rivaroxaban (86.08% ± 10.23%), apixaban (68.26% ± 10.82%), dabigatran (41.63% ± 12.26%), low-molecular-weight heparin (41.03% ± 9.60%), ximelagatran (37.81% ± 15.87%), aspirin (35.62% ± 20.60%), warfarin (9.89% ± 9.07%), and placebo (4.56% ± 6.37%). Ranking based on clinically relevant bleeding events was as follows: fondaparinux (14.53% ± 15.25%), ximelagatran (18.93% ± 17.49%), rivaroxaban (23.86% ± 15.14%), dabigatran (28.30% ± 14.18%), edoxaban (38.76% ± 24.25%), low-molecular-weight heparin (53.28% ± 8.40%), apixaban (71.81% ± 10.92%), placebo (76.26% ± 14.61%), aspirin (86.32% ± 25.74%), and warfarin (87.95% ± 11.27%). No statistically significant heterogeneity was observed between trials.<h4>Conclusions and relevance</h4>According to our results, all anticoagulant drugs showed some effectiveness for VTE prophylaxis. Our ranking indicated that fondaparinux and rivaroxaban were safer and more effective than other anticoagulant drugs for patients undergoing THA or TKA.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0250096&type=printable |
| spellingShingle | Tailai He Fei Han Jiahao Wang Yihe Hu Jianxi Zhu Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. PLoS ONE |
| title | Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. |
| title_full | Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. |
| title_fullStr | Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. |
| title_full_unstemmed | Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. |
| title_short | Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: A PRISMA-compliant Bayesian network meta-analysis. |
| title_sort | efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty a prisma compliant bayesian network meta analysis |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0250096&type=printable |
| work_keys_str_mv | AT tailaihe efficacyandsafetyofanticoagulantsforpostoperativethrombophylaxisintotalhipandkneearthroplastyaprismacompliantbayesiannetworkmetaanalysis AT feihan efficacyandsafetyofanticoagulantsforpostoperativethrombophylaxisintotalhipandkneearthroplastyaprismacompliantbayesiannetworkmetaanalysis AT jiahaowang efficacyandsafetyofanticoagulantsforpostoperativethrombophylaxisintotalhipandkneearthroplastyaprismacompliantbayesiannetworkmetaanalysis AT yihehu efficacyandsafetyofanticoagulantsforpostoperativethrombophylaxisintotalhipandkneearthroplastyaprismacompliantbayesiannetworkmetaanalysis AT jianxizhu efficacyandsafetyofanticoagulantsforpostoperativethrombophylaxisintotalhipandkneearthroplastyaprismacompliantbayesiannetworkmetaanalysis |